Biotechnology
Scientists create first mouse model for rare genetic encephalopathy
FDA Approves Replimune Cancer Therapy as Biotech Hubs Shift
Genetic variants linked to food preferences and metabolic health risks
New research reveals genetic factors that shape food preferences and increase risks for obesity and type 2 diabetes, offering insights into personalized nutrition.
Breakthrough gene map identifies new heart failure treatment targets
UC San Diego researchers unveil the most detailed gene regulation map in human heart failure, identifying new therapeutic targets and cell specific gene control mechanisms.
Trump tariffs on generic drugs could raise prices and cause shortages
The Trump administration’s plan to impose tariffs on imported generic drugs could reshape U.S. pharmaceutical supply chains. Learn how this policy may affect drug prices, patient access, and domestic manufacturing.
Genetic Markers Offer New Hope for Early Glaucoma Detection and Prevention
Research reveals genetic information may predict glaucoma onset and progression, enabling earlier intervention to prevent irreversible vision loss. Learn how targeted screening could change eye care.
U.S. Biotech Restrictions on China Risk Alienating Critical Scientific Talent, Experts Warn
As Washington tightens scrutiny on Chinese linked biotech collaborations, leading researchers caution that sweeping restrictions may harm U.S. innovation by deterring top international scientists and disrupting global research networks.
FDA Fast Tracks Generative AI Tools for Radiology: A Breakthrough in Diagnostic Efficiency
The FDA has designated two generative AI devices as breakthrough technologies for interpreting chest X rays and drafting radiology reports. Discover what this means for patient care and clinical workflows.
Regenxbio Defies FDA Hesitation, Pushes Forward with Duchenne Gene Therapy Submission
Regenxbio moves ahead with FDA submission for its Duchenne muscular dystrophy gene therapy, RGX 202, after regulators initially requested additional trial data. What this means for patients and the future of genetic treatments.
Gene Editing Pioneer Secures $230 Million and Strategic Chinese Partnership in High Stakes Biotech Launch
A groundbreaking gene editing startup has emerged with $230 million in funding and a strategic Chinese licensing agreement, signaling a major shift in biotech innovation. Explore the implications for global healthcare and precision medicine.